Arch Biopartners Submits Orphan Drug Application for AB569

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Arch Biopartners Submits Orphan Drug Application for AB569 to European Medicines Agency

TORONTO, ONTARIO--(Marketwired - Feb. 3, 2016) - Arch Biopartners Inc. (Arch, or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced they have submitted an application for orphan drug designation to the European Medicines Authority (EMA) for AB569 in the treatment of Pseudomonas aeruginosa ( P. aeruginosa) pulmonary infections in patients with cystic fibrosis.

The EMA is currently reviewing the completeness of the application before initiating the official review process. It is expected that the Committee for Orphan Medicinal Products (COMP) will begin review of the application in approximately 30 days and will provide an opinion on the application that is forwarded to the European Commission (EC) by the end of May 2016. The EC will then decide whether or not to approve the orphan drug designation for AB569.

An orphan drug designation in Europe provides incentives to a pharmaceutical company to develop a medicine for a rare disease. Such incentives include protocol assistance, which allows the drug company to get guidance from the EMA on the types of clinical studies needed to demonstrate the quality, benefits and risks of the new medicine. Other incentives include access to a centralized authorization procedure and lower regulatory fees whereby a company can make a single new drug application to the EMA, resulting in a single drug approval decision from the EC, valid in all European Union Member States.

Orphan medicines approved by the EC further benefit from ten years of protection from market competition from similar drugs targeting the same indication.

In November 2015, the U.S. F.D.A. granted orphan drug designation for the combination of two active ingredients of AB569: sodium nitrite and ethylenediaminetetraacetic acid. AB569 is to be administered to patients as a nebulized (inhaled) solution. AB569 was invented at the University of Cincinnati in the lab of Dr. Daniel Hassett.

The Clinical Need for a New Treatment for P. aeruginosa Pulmonary Infections

P. aeruginosa is a significant cause of bacterial respiratory infections in patients who have cystic fibrosis (CF) or chronic obstructive pulmonary disease. It is also a common cause of pneumonia.

The mean prevalence of CF is approximately 0.74 cases per 10,000 people among 27 European Union countries, which is well below the defined limit for a rare or orphan disease. The mucoid form of P. aeruginosa , often found in CF patients, is a very challenging infection to treat due to its high resistance to both antibiotics and phagocyte-mediated killing. Once patients present with the mucoid form of P. aeruginosa , their overall lung function precipitously declines, resulting in a poor prognosis.

Thus, there is an urgent clinical need for the development of novel effective treatments in this area. AB569 constitutes an innovative potential treatment for dealing with mucoid and nonmucoid P. aeruginosa pulmonary infections that are resistant to traditional antibiotics.

Cystic Fibrosis

CF is an autosomal recessive genetic disease that causes abnormalities of the CF transmembrane conductance regulator (CFTR) protein. CFTR is a critical regulator of sweat, digestive fluids, and mucus production.

CF patients are predisposed to lung infections due to abnormal mucus production in the lungs and airways. P. aeruginosa infects 40% of CF patients between the ages of 6 and 10 years of age. By the age of 17, the frequency of infection increases to 60% and reaches approximately 75% of all CF patients between the ages of 25 and 34.

About Arch Biopartners

Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, develop the most promising intellectual property, and create value for its investors.

Arch has established a diverse portfolio that includes MetaMx, which targets illusive brain tumor initiating cells; AB569, a potential new treatment for Pseudomonas aeruginosa pulmonary infections; and, Metablok, a potential treatment for sepsis and cancer metastasis. MetaMx and AB569 are both on track to enter human clinical trials in late 2016.

For more information on Arch Biopartners, other public documents Arch has filed on SEDAR and its technologies including, please visit www.archbiopartners.com .

The Company has 53,189,679 common shares outstanding.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Richard Muruve Chief Executive Officer Arch Biopartners, Inc. 647-428-7031 info@archbiopartners.com Babak Pedram Investor Relations Virtus Advisory Group Inc. 416-644-5081 bpedram@virtusadvisory.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 34

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
SAFE Wins Missouri Guard UH-60 Platform Contract Again

Updated Category News Views 30

Helicopter maintenance is one of those businesses where a few feet of floor space can matter more than a glossy brochure full of promises. SAFE Structure Designs has landed a new contract to supply custom wraparound maintenance platforms for UH-60 helicopters at the Missouri Army National Guard facility in Springfield, Missouri. No price was disclosed, no delivery...

Continue Reading
LGT Middle East Win Highlights Patient Private Banking

Updated Category News Views 120

A trophy in Dubai is not a balance sheet, but it can be a useful calling card when the clientele measures relationships in decades rather than quarters. LGT Middle East was named Best Pure Play Private Bank at the WealthBriefing MENA Awards 2026, at a ceremony held in Dubai on November 18. For a family-owned wealth manager working with Middle Eastern families, that sort...

Continue Reading
Dubai's 2028 Fire Congress Puts Global Safety Tech on Stage

Updated Category News Views 77

Fire engines, wildfires, dense towers, and AI are all colliding in Dubai's next big public-safety moment. The World Fire Congress has handed its 2028 host role to Dubai, making this the first time the biennial gathering of global fire and emergency-service leaders will land in the Middle East. That is not a quarterly earnings event, and nobody ought to pretend it is....

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 199

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 72

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 87

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading
Ajman Forum Puts Algorithmic Messaging Under Scrutiny

Updated Category News Views 53

Algorithms do not merely shuffle posts anymore; they can scramble confidence in the institutions people depend on. That was the serious undercurrent at Ajman Media Forum 2026 – THE SIGNAL, where a session on who leads the government message in an algorithm-driven age brought the discussion back to an uncomfortable reality: communication, cybersecurity and social...

Continue Reading
Makera A1S Tests the Desktop CNC Metal-Cutting Promise

Updated Category News Views 21

Aluminum chips are where desktop-machine marketing stops bluffing, and Makera is leaning right into that test with the A1S. The company opened global pre-orders on November 18 for a machine aimed squarely at the awkward middle ground: users who have outgrown entry-level hobby gear but do not have room, budget, or patience for a full industrial setup. That is a real market...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 94

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading

Top 5 Most Recently Viewed Articles

Gamehaus Holdings Inc. Launches Strategic Share Buyback Plan

Updated Category News Views 222

Gamehaus Holdings Inc. Introduces New Share Repurchase Program Gamehaus Holdings Inc. (Nasdaq: GMHS), a leading mobile game publisher focused on technology, has announced a significant move aimed at returning value to its shareholders. The company has authorized a share repurchase program that allows it to buy back up to US$5 million of its Class A ordinary shares. This...

Continue Reading
AMN Healthcare's Upcoming Earnings Call: What to Expect

Updated Category News Views 191

AMN Healthcare's Upcoming Earnings Conference Call AMN Healthcare Services, Inc. (NYSE: AMN) has announced an important conference call planned for Thursday, November 6, 2025, at 5:00 p.m. Eastern Time. This event aims to provide valuable insights into the company’s third quarter financial results and the outlook for the fourth quarter of the same year. Investors and...

Continue Reading
J&T Express Marks Profit Milestone in 2024 with Strong Growth

Updated Category News Views 520

J&T Express Achieves Profit Milestone Amid Impressive Growth J&T Global Express Limited, commonly known as J&T Express, reported remarkable achievements in its recent annual results, highlighting significant milestones in revenue growth and profitability. In a remarkable development, the company made a substantial leap in the logistics sector, marking its first full-year...

Continue Reading
Innovative Smart Walking Stick Enhances Safety for Users

Updated Category News Views 207

Introducing the Artisan Smart Walking Stick In a world where mobility and safety are paramount, innovation plays a crucial role in enhancing the lives of individuals. The Artisan Smart Walking Stick is a groundbreaking invention emerging from dedicated inventors focused on providing greater independence and safety for users like the elderly and visually impaired. The...

Continue Reading
Golden Ocean Group Limited Announces AGM Resolutions and Results

Updated Category News Views 156

Golden Ocean Group Limited 2025 Annual General Meeting Overview Golden Ocean Group Limited, known by the ticker symbols Oslo:GOGL and Nasdaq:GOGL, recently held its Annual General Meeting (AGM), an essential gathering designed to keep shareholders informed and involved in the company's progress and direction. The meeting showcased the financial health of the organization,...

Continue Reading